References
1. Greene C, Vadlamudi G, Newton D, Foxman B, Xi
C. The influence of biofilm formation and multidrug
resistance on environmental survival of clinical and
environmental isolates of Acinetobacter baumannii.
Am J Infect Control. 2016;44(5):e65-71.
2. Ahuatzin-Flores OE, Torres E, Chávez-Bravo E.
Acinetobacter baumannii, a multidrug-resistant
opportunistic pathogen in new habitats: A systematic
review. Microorganisms. 2024;12(4):644.
3. Kim SW, Oh MH, Jun SH, Jeon H, Kim SI, Kim K,
et al. Outer membrane Protein A plays a role in
pathogenesis of Acinetobacter nosocomialis.
Virulence. 2016;7(4):413-26.
4. Han L, Gao Y, Liu Y, Yao S, Zhong S, Zhang S, et
al. An outer membrane protein YiaD contributes to
adaptive resistance of meropenem in Acinetobacter
baumannii. Microbiol Spectr. 2022;10(2):e00173-22.
5. Zhang R, Li D, Fang H, Xie Q, Tang H, Chen L. Irondependent mechanisms in Acinetobacter baumannii:
pathogenicity and resistance. JAC Antimicrobial
Resistance. 2025;7.
6. Sheldon JR, Skaar EP. Acinetobacter baumannii can
use multiple siderophores for iron acquisition, but
only acinetobactin is required for virulence. PLoS
Pathog. 2020;16(10):e1008995.
7. Karakalpakidis D, Papadopoulos T, Paraskeva M,
Tsitlakidou M-E, Vagdatli E, Katsifa H, et al. When
the Last Line Fails: Characterization of ColistinResistant Acinetobacter baumannii Reveals High
Virulence and Limited Clonal Dissemination in Greek
Hospitals. Pathogens. 2025;14(8):730.
8. Mack Andrew R, Hujer Andrea M, Mojica Maria F,
Taracila Magdalena A, Feldgarden M, Haft Daniel H,
et al. β-Lactamase diversity in Acinetobacter
baumannii. Antimicrob Agents Chemother.
2025;69(3):e00784-24.
9. Jain M, Sharma A, Sen M, Rani V, Gaind R, Suri J.
Phenotypic and molecular characterization of
Acinetobacter baumannii isolates causing lower
respiratory infections among ICU patients. Microb
Pathog. 2019;128:75-81.
10. Humphries R, Bobenchik AM, Hindler JA, Schuetz
AN. Overview of changes to the clinical and
laboratory standards institute performance standards
for antimicrobial susceptibility testing, M100. J Clin
Microbiol. 2021;59(12):10.1128/jcm. 00213-21.
11. McConnell MJ, Pérez-Ordóñez A, Pérez-Romero P,
Valencia R, Lepe JA, Vázquez-Barba I, et al.
Quantitative real-time PCR for detection of
Acinetobacter baumannii colonization in the hospital
environment. J Clin Microbiol. 2012;50(4):1412-4.
12. Lannan FM, O'Conor D K, Broderick JC, Tate JF,
Scoggin JT, Moran NA, et al. Evaluation of Virulence
Gene Expression Patterns in Acinetobacter baumannii
Using Quantitative Real-Time Polymerase Chain
Reaction Array. Mil Med. 2016;181(9):1108-13.
13. Organization WH. WHO bacterial priority
pathogens list, 2024: bacterial pathogens of public
health importance, to guide research, development,
and strategies to prevent and control antimicrobial
resistance: WHO; 2024.
14. Jesudason T. WHO publishes updated list of
bacterial priority pathogens. Lancet Microbe. 2024;5.
15. Moradi J, Hashemi FB, Bahador A. Antibiotic
resistance of Acinetobacter baumannii in Iran: a
systemic review of the published literature. Osong
Public Health Res Perspect. 2015;6(2):79-86.
16. Alizadeh H, Khodavandi A, Alizadeh F, Bahador N.
Phenotypic and Genotypic Identification of
Metallobetalactamase Genes in Resistant
Enterobacteriaceae Isolated from Medical Centers in
Isfahan. Novel Biomed. 2024;12(1):31-42.
17. Azizi O, Fereshteh S, Naşiri O, Ghorbani M, Barzi
SM, Badmasti F. The occurrence and characterization
of class I, II, and III integrons among carbapenemaseproducing clinical strains of Acinetobacter baumannii
in Tehran, Iran. Jundishapur J Microbiol.
2021;14(6):1-13.
18. Abed AB, Korcan SE, Güngör S. Antibiotics profile
map of clinical A. baumannii strains isolated from
health institutions in Turkey: a database search study
and analysis of publications from 2011 to 2022. Bull
Nat Res Cent. 2023;47(1):15.
19. Alharbi O, Al-Said HM, Ashgar SS, Jalal NA,
Faidah H, Momenah AM, et al. Prevalence and
Antibiogram Pattern of Acinetobacter baumannii from
2013 to 2023 in a Tertiary Care Hospital in the Western Region of Saudi Arabia. Antibiotics.
2025;14(3):274.
20. Zahra N, Zeshan B, Ali QMM, Ishaq M, Afzal M,
Ahmed N. Phenotypic and genotypic evaluation of
antibiotic resistance of Acinetobacter baumannii
bacteria isolated from surgical intensive care unit
patients in Pakistan. Jundishapur J Microbiol.
2021;14(4).
21. ECDC E. Annual Epidemiological Report for 2022.
Stockholm; 2013.
22 .Boutzoukas A, Doi Y. The global epidemiology of
carbapenem-resistant Acinetobacter baumannii. JAC
Antimicrob Resist. 2025;7(4):dlaf134.
23. Azimi L, Armin S, Samadi Kafil H, Abdollahi N,
Ghazvini K, Hasanzadeh S, et al. Evaluation of
phenotypic and genotypic patterns of aminoglycoside
resistance in the Gram-negative bacteria isolates
collected from pediatric and general hospitals. Mol
Cell Pediatrics. 2022;9(1):2.
24. Rashvand P, Peymani A, Mohammadi M, Karami A,
Samimi R, Hajian S, et al. Molecular survey of
aminoglycoside-resistant Acinetobacter baumannii
isolated from tertiary hospitals in Qazvin, Iran. New
Microbes New Infect. 2021;42:100883.
25. Waterlow NR, Cooper BS, Robotham JV, Knight
GM. Antimicrobial resistance prevalence in
bloodstream infection in 29 European countries by age
and sex: An observational study. PLoS Medicine.
2024;21(3):e1004301.
26. Humphries RM, Janssen H, Hey-Hadavi JH, Hackel
M, Sahm D. Multidrug-resistant Gram-negative
bacilli recovered from respiratory and blood
specimens from adults: the ATLAS surveillance
program in European hospitals, 2018–2020. Int J
Antimicrob Agent. 2023;61(2):106724.
27. Pormohammad A, Mehdinejadiani K, Gholizadeh P,
Nasiri MJ, Mohtavinejad N, Dadashi M, et al. Global
prevalence of colistin resistance in clinical isolates of
Acinetobacter baumannii: A systematic review and
meta-analysis. Microb Pathog. 2020;139:103887.
28. El-Shazly S, Dashti A, Vali L, Bolaris M, Ibrahim
AS. Molecular epidemiology and characterization of
multiple drug-resistant (MDR) clinical isolates of
Acinetobacter baumannii. Int J Infect Dis.
2015;41:42-9.
29. Sarhaddi N, Dolatabadi S, Amel Jamehdar S. Drug
resistance pattern of carbapenem-resistant
Acinetobacter baumannii isolated from a referral burn
center in northeast of Iran. J Mashhad Univ Med Sci.
2016;59(1):1-8.
30. de Souza J, D’Espindula HRS, Ribeiro IdF,
Gonçalves GA, Pillonetto M, Faoro H. Carbapenem
Resistance in Acinetobacter baumannii: Mechanisms,
Therapeutics, and Innovations. Microorganisms.
2025;13(7):1501.
31. Uppalapati SR, Sett A, Pathania R. The outer
membrane proteins OmpA, CarO, and OprD of
Acinetobacter baumannii confer a two-pronged
defense in facilitating its success as a potent human
pathogen. Fron Microbiol. 2020;11:589234.
32. Castanheira M, Mendes RE, Gales AC. Global
Epidemiology and Mechanisms of Resistance of
Acinetobacter baumannii-calcoaceticus Complex .
Clin Infect Dis. 2023;76 (Supplement_2):S166-S78.
33. Zhang Y, Li Z, He X, Ding F, Wu W, Luo Y, et al.
Overproduction of efflux pumps caused reduced
susceptibility to carbapenem under consecutive
imipenem-selected stress in Acinetobacter baumannii.
Infect Drug Resist. 2018;11(null):457-67.
34. Conde-Pérez K, Vázquez-Ucha JC, Álvarez-Fraga
L, Ageitos L, Rumbo-Feal S, Martínez-Guitián M, et
al. In-Depth Analysis of the Role of the Acinetobactin
Cluster in the Virulence of Acinetobacter baumannii.
Front Microbiol. 2021;12:752070.
35. Artuso I, Poddar H, Evans BA, Visca P. Genomics
of Acinetobacter baumannii iron uptake. Microb
Genom. 2023;9(8):001080.
36. Kim M, Kim DY, Song WY, Park SE, Harrison SA,
Chazin WJ, et al. Distinctive Roles of Two
Acinetobactin Isomers in Challenging Host
Nutritional Immunity. mBio. 2021;12(5):e0224821.
مجله علوم پزشکی پارس